Evaluación de lenalidomida en el tratamiento del mieloma múltiple, la mielofibrosis y el síndrome mielodisplásico

LDM is well-tolerated and produces sustained clinical benefits, especially in MM and MF. More studies are needed for in-depth examination of treatment duration, new indications and the use of treatments combined with other drugs.